The Nicomide Improvement in Clinical Outcomes Study (NICOS): results of an 8-week trial.
Total years in practice: 3
January 01, 2006
Neil M Niren, Helen M Torok
Cutis. 2006 Jan;77(1 Suppl):17-28. PMID: 16871775
Functional Medicine, Naturopathic Medicine
The Nicomide Improvement in Clinical Outcomes Study (NICOS) was an open-label, multicenter, prospective cohort study designed to assess the clinical utility of oral pharmacologic doses of nicotinamide and zinc in 198 patients with acne vulgaris and/or rosacea. The study's primary efficacy measures were patient global evaluation and patient evaluation of the percentage of reduction in inflammatory lesions after 4 and 8 weeks of treatment; overall patient satisfaction also was recorded. The study formulation consisted of nicotinamide 750 mg, zinc 25 mg, copper 1.5 mg, and folic acid 500 microg, marketed as Nicomide (Nic/Zn). Nic/Zn was designed to deliver adequate concentrations of nicotinamide and zinc to effectively treat inflammatory cutaneous conditions with a safety profile suitable for long-term administration. After a relatively short treatment period of 4 weeks, the number of patients enrolled in NICOS who reported improvement was significantly greater (P50% reduction in lesions) improvement after 4 weeks of treatment (P
Get more information via email